通过克隆选择识别的向HER2的IgE抗体通过免疫刺激活动限制了乳腺癌的生长
Lais C G F Palhares1,2, Melanie Grandits1,2, Katie Stoker1,3
1St. John's Institute of Dermatology, School of Basic & Medical Biosciences, & KHP Centre for Translational Medicine, King's College London, London, SE1 9RT, UK.
Journal of experimental & clinical cancer research : CR
|February 11, 2025
概括
研究人员开发了一个新的平台,以创建针对HER2表达癌症的新型IgE抗体. 这些工程IgE抗体在临床前模型中显示出显著的抗瘤活性和免疫刺激.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 生物技术是生物技术.
背景情况:
- 瘤向的IgE抗体利用免疫效应机制产生抗癌效应.
- 缺乏用于新型IgE抗体开发,选择和评估的专用平台.
研究的目的:
- 建立一个平台,用于产生和选择针对HER2的新型IgE抗体.
- 评估工程抗HER2IgE抗体的抗瘤疗效和免疫刺激性质.
主要方法:
- 建立了一个IgE抗体治疗设计平台.
- 使用菌体显示器生成了针对人类表皮生长因子受体2 (HER2) 的IgE抗体组.
- 主要候选人是根据生物物理性质,HER2反应性和Fc介导的抗瘤活性在体外进行选择的.
- 功能性评估在免疫能力较强的老鼠和对HER2阳性乳腺癌的人性化小鼠模型中进行.
主要成果:
- 设计的IgE抗体诱导了对HER2表达瘤细胞的脱粒和抗体依赖的细胞细胞毒性.
- 在老鼠和人性化小鼠模型中,IgE抗体26表现出显著的抗瘤活性.
- 治疗导致增强免疫细胞透,促炎特征,并在瘤微环境中降低癌症进展途径的调节.
结论:
- 这项研究为设计和产生具有免疫刺激和瘤限制作用的抗HER2 IgE抗体提供了一个新的平台.
- 开发的IgE抗体在HER2表达性癌症中显示出治疗应用的前景.
- 这项工作可能为抗体工程在难以治疗的癌症中开辟新的途径.
更多相关视频
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
16.6K
08:29Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
72
相关概念视频
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:38Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
01:27Tumor Immunotherapy
464
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
464
02:34Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K